Progenics Pharmaceuticals Sets Second Quarter 2019 Financial Results and Business Update Call for August 9

NEXT STORY
INmune Bio Co-Founder and CEO RJ Tesi Presents at Cambridge Healthcare Institute’s 7th Annual Immuno-Oncology Summit
PREV STORY
I-Mab Biopharma and TRACON Pharmaceuticals Announce Dosing of the First Patient in the U.S. Phase 1 Clinical Trial of the CD73 Antibody TJD5 in Patients with Advanced Solid Tumors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Cellworks Personalized Biosimulation Clinical Trial Predicted ATO and ATRA Therapy Response in APL Patients with 93% Accuracy

author_avatar
NASDAQ Market News

Congresswoman Gwen Moore Adds Voice to Groundswell of Support for Reducing Nicotine in Cigarettes, Encourages HHS Secretary Becerra to Take Action to Save Lives and End Health Disparities

author_avatar
NASDAQ Market News

Aravax Presents Positive PVX108 Phase 1 Clinical Trial Results at AAAAI 2019 Annual Meeting

author_avatar
NASDAQ Market News